| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.1 | $0-$5k | 0.00 |
Summary
A vulnerability labeled as problematic has been found in Bioinformatics htmLawed up to 1.1.3. Affected by this vulnerability is an unknown functionality. The manipulation results in cross site scripting. This vulnerability is identified as CVE-2009-0404. The attack can be executed remotely. There is not any exploit available.
Details
A vulnerability was found in Bioinformatics htmLawed up to 1.1.3. It has been classified as problematic. Affected is an unknown part. The manipulation with an unknown input leads to a cross site scripting vulnerability. CWE is classifying the issue as CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. This is going to have an impact on integrity. CVE summarizes:
Multiple cross-site scripting (XSS) vulnerabilities in Bioinformatics htmLawed 1.1.3 and 1.1.4 allow remote attackers to inject arbitrary web script or HTML via invalid Cascading Style Sheets (CSS) expressions in the style attribute, which is processed by Internet Explorer 7.
The weakness was released 01/29/2009 (Website). The advisory is available at securityfocus.com. This vulnerability is traded as CVE-2009-0404 since 02/03/2009. It is possible to launch the attack remotely. The exploitation doesn't require any form of authentication. Successful exploitation requires user interaction by the victim. The technical details are unknown and an exploit is not available. This vulnerability is assigned to T1059.007 by the MITRE ATT&CK project.
It is declared as highly functional.
A possible mitigation has been published before and not just after the disclosure of the vulnerability.
The vulnerability is also documented in the databases at X-Force (48333), SecurityFocus (BID 33507†), OSVDB (51650†) and Secunia (SA33655†). If you want to get best quality of vulnerability data, you may have to visit VulDB.
Product
Vendor
Name
Version
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.3VulDB Meta Temp Score: 4.1
VulDB Base Score: 4.3
VulDB Temp Score: 4.1
VulDB Vector: 🔍
VulDB Reliability: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Highly functional
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔍
Timeline
01/28/2009 🔍01/29/2009 🔍
01/29/2009 🔍
01/29/2009 🔍
01/29/2009 🔍
02/03/2009 🔍
02/03/2009 🔍
03/17/2015 🔍
10/27/2018 🔍
Sources
Advisory: securityfocus.com⛔Status: Confirmed
Confirmation: 🔍
CVE: CVE-2009-0404 (🔍)
GCVE (CVE): GCVE-0-2009-0404
GCVE (VulDB): GCVE-100-46266
X-Force: 48333 - htmLawed unspecified cross-site scripting
SecurityFocus: 33507 - htmLawed Multiple Unspecified Cross-Site Scripting Vulnerabilities
Secunia: 33655 - htmLawed Unspecified Cross-Site Scripting Vulnerabilities, Less Critical
OSVDB: 51650 - htmLawed Crafted CSS Expressions XSS
Entry
Created: 03/17/2015 16:11Updated: 10/27/2018 04:47
Changes: 03/17/2015 16:11 (54), 10/27/2018 04:47 (7)
Complete: 🔍
Cache ID: 216::103
If you want to get best quality of vulnerability data, you may have to visit VulDB.
No comments yet. Languages: en.
Please log in to comment.